Ascletis completes denifanstat (asc40) pre-nda consultation with china national medical products administration

- denifanstat (asc40) met all primary, key secondary and secondary efficacy endpoints (itt analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a phase iii randomized, double-blind, placebo-controlled, multicenter clinical trial. hong kong , oct. 14, 2025 /prnewswire/ -- ascletis pharma inc. (hkex: 1672, "ascletis") announces today that it recently completed the pre-new drug application (nda) consultation with china national medical products administration (nmpa) for denifanstat (asc40) for the treatment of moderate-to-severe acne vulgaris and plans to submit an nda soon.
ASC Ratings Summary
ASC Quant Ranking